Andrew A. Protter

Medicine · Health Sciences

46h-index7.5kcitations113works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(18), Heart Failure Treatment and Management(14), Melanoma and MAPK Pathways(13), Glioma Diagnosis and Treatment(10), DNA Repair Mechanisms(9)

Publications113 total

Data from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S5 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S6 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S6 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S5 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S3 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S3 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S2 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S2 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Data from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S4 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S4 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Supplementary Information from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S1 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Supplementary Information from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Figure S1 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
2023Open Access
Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses
Scientific Reports·2022· 6 citedOpen Access
Novel small molecules induced ROS accumulation and antitumor activity based on an oxidative stress gene signature.
Journal of Clinical Oncology·2018· 3 cited
Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Molecular Cancer Therapeutics·2017· 71 citedOpen Access
Abstract B30: Talazoparib efficacy is enhanced by noncytotoxic doses of temozolomide-mediated DNA damage in prostate cancer cell lines
Molecular Cancer Research·2017
page 1 of 6Next →

Frequent Co-authors

Satyanarayana Medicherla(10), Sarvajit Chakravarty(10), Ann M. Kapoun(9), Sundeep Dugar(9), Linda S. Higgins(9), Ying Jing(6), Sebastián Bernales(5), Iván E. Alfaro(5), Andrew Lam(5), George F. Schreiner(5), Gilbert O’Young(5), Roger White(4), Irene Kerr(4), Alison Murphy(4), Glenn McEnroe(4), Lawrence W. Stanton(3), N. Stephen Pollitt(3), Jessica O’Rear(3), Ute Schellenberger(3), Satya Medicherla(3)